These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26395031)

  • 1. Potential role for inhibition of protein phosphatase 2A tumor suppressor in salivary gland malignancies.
    Routila J; Mäkelä JA; Luukkaa H; Leivo I; Irjala H; Westermarck J; Mäkitie A; Ventelä S
    Genes Chromosomes Cancer; 2016 Jan; 55(1):69-81. PubMed ID: 26395031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The concept of the okadaic acid class of tumor promoters is revived in endogenous protein inhibitors of protein phosphatase 2A, SET and CIP2A, in human cancers.
    Fujiki H; Sueoka E; Watanabe T; Suganuma M
    J Cancer Res Clin Oncol; 2018 Dec; 144(12):2339-2349. PubMed ID: 30341686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer.
    González-Alonso P; Cristóbal I; Manso R; Madoz-Gúrpide J; García-Foncillas J; Rojo F
    Tumour Biol; 2015 Aug; 36(8):5753-5. PubMed ID: 26234767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
    Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
    EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential.
    Cristóbal I; Manso R; Rincón R; Caramés C; Senin C; Borrero A; Martínez-Useros J; Rodriguez M; Zazo S; Aguilera O; Madoz-Gúrpide J; Rojo F; García-Foncillas J
    Mol Cancer Ther; 2014 Apr; 13(4):938-47. PubMed ID: 24448818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular characterization of salivary gland malignancy using the Smgb-Tag transgenic mouse model.
    Mäkitie AA; Pintor Dos Reis P; Arora S; Macmillan C; Warner GC; Sukhai M; Dardick I; Perez-Ordonez B; Wells R; Brown D; Gilbert R; Freeman J; Gullane P; Irish J; Kamel-Reid S
    Lab Invest; 2005 Aug; 85(8):947-61. PubMed ID: 15880136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1.
    Kauko O; Imanishi SY; Kulesskiy E; Yetukuri L; Laajala TD; Sharma M; Pavic K; Aakula A; Rupp C; Jumppanen M; Haapaniemi P; Ruan L; Yadav B; Suni V; Varila T; Corthals GL; Reimand J; Wennerberg K; Aittokallio T; Westermarck J
    J Biol Chem; 2020 Mar; 295(13):4194-4211. PubMed ID: 32071079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.
    Janghorban M; Farrell AS; Allen-Petersen BL; Pelz C; Daniel CJ; Oddo J; Langer EM; Christensen DJ; Sears RC
    Proc Natl Acad Sci U S A; 2014 Jun; 111(25):9157-62. PubMed ID: 24927563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CIP2A inhibits PP2A in human malignancies.
    Junttila MR; Puustinen P; Niemelä M; Ahola R; Arnold H; Böttzauw T; Ala-aho R; Nielsen C; Ivaska J; Taya Y; Lu SL; Lin S; Chan EK; Wang XJ; Grènman R; Kast J; Kallunki T; Sears R; Kähäri VM; Westermarck J
    Cell; 2007 Jul; 130(1):51-62. PubMed ID: 17632056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer.
    Farrell AS; Allen-Petersen B; Daniel CJ; Wang X; Wang Z; Rodriguez S; Impey S; Oddo J; Vitek MP; Lopez C; Christensen DJ; Sheppard B; Sears RC
    Mol Cancer Res; 2014 Jun; 12(6):924-39. PubMed ID: 24667985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.
    Yu HC; Hung MH; Chen YL; Chu PY; Wang CY; Chao TT; Liu CY; Shiau CW; Chen KF
    Cell Death Dis; 2014 Jul; 5(7):e1359. PubMed ID: 25077545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of β-Catenin Phosphorylation by PR55β in Adenoid Cystic Carcinoma.
    Ishibashi K; Ishii K; Sugiyama G; Kamata YU; Suzuki A; Kumamaru W; Ohyama Y; Nakano H; Kiyoshima T; Sumida T; Yamada T; Mori Y
    Cancer Genomics Proteomics; 2018; 15(1):53-60. PubMed ID: 29275362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia.
    Richard NP; Pippa R; Cleary MM; Puri A; Tibbitts D; Mahmood S; Christensen DJ; Jeng S; McWeeney S; Look AT; Chang BH; Tyner JW; Vitek MP; Odero MD; Sears R; Agarwal A
    Oncotarget; 2016 Dec; 7(51):84214-84227. PubMed ID: 27705940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein phosphatase 2A in non-small cell lung cancer cells.
    Kim MO; Choe MH; Yoon YN; Ahn J; Yoo M; Jung KY; An S; Hwang SG; Oh JS; Kim JS
    Biochem Pharmacol; 2017 Nov; 144():78-89. PubMed ID: 28813646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Submandibular gland adenocarcinoma of intercalated duct origin in Smgb-Tag mice.
    Dardick I; Ho J; Paulus M; Mellon PL; Mirels L
    Lab Invest; 2000 Nov; 80(11):1657-70. PubMed ID: 11092526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56.
    Wang J; Okkeri J; Pavic K; Wang Z; Kauko O; Halonen T; Sarek G; Ojala PM; Rao Z; Xu W; Westermarck J
    EMBO Rep; 2017 Mar; 18(3):437-450. PubMed ID: 28174209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between high expression of phosphorylated Akt and mammalian target of rapamycin and improved survival in salivary gland adenoid cystic carcinoma.
    Ouyang DQ; Liang LZ; Ke ZF; Zheng GS; Weng DS; Yang WF; Su YX; Liao GQ
    Head Neck; 2017 Jun; 39(6):1145-1154. PubMed ID: 28230926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma.
    Yu HC; Chen HJ; Chang YL; Liu CY; Shiau CW; Cheng AL; Chen KF
    Biochem Pharmacol; 2013 Feb; 85(3):356-66. PubMed ID: 23178652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes.
    Niemelä M; Kauko O; Sihto H; Mpindi JP; Nicorici D; Pernilä P; Kallioniemi OP; Joensuu H; Hautaniemi S; Westermarck J
    Oncogene; 2012 Sep; 31(39):4266-78. PubMed ID: 22249265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
    Liu H; Gu Y; Wang H; Yin J; Zheng G; Zhang Z; Lu M; Wang C; He Z
    Oncotarget; 2015 Jun; 6(17):14913-25. PubMed ID: 25945834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.